Le Lézard
Classified in: Health
Subject: MAT

Enhance Patient Results with Dr. PRP's New Cellulam Post Procedure Lotion with DNA Repair Enzymes


Dr. PRP's Cellulam Post Procedure Lotion repairs the appearance of UV damage and sun spots in as little as four weeks.

HOUSTON, Oct. 4, 2022 /PRNewswire-PRWeb/ -- Dr. PRP's new Cellulam Post Procedure Lotion with DNA Repair Enzymes improves the appearance of UV damage and sun spots in as little as four weeks. By using after in-office treatments and as part of routine skin care regimens, patients have enhanced outcomes and improved satisfaction.

Made in the USA using only the highest quality active ingredients, the Cellulam Post Procedure Lotion targets damage and supports new cellular regeneration.

Key DNA repair enzymes include:

Patients use the product twice per day and it is easily integrated into existing in-office skin care regimens.

"Increase credibility with your patients with incredible results that compliment a wide variety of procedures you're already utilizing in your practice" ? George Bretz, CCP, LP, Managing Partner

Partnering with Dr. PRP USA means enhancing patient results and subsequently their satisfaction.

Call 844-377-7787 (DR-PRP-USA) for more information and to order or visit http://www.drprpusa.com.

About Dr. PRP USA LLC
Dr. PRP USA LLC is committed to regenerative solutions to promote natural healing and solve today's medical issues. As a privately held company, we make cutting-edge healthcare more affordable and accessible. In addition to the new Cellulam Post Procedure Lotion with DNA Repair Enzymes, Dr. PRP USA provides PRP kits, centrifuges, activators, and other skincare products.

Media Contact

George Bretz, Dr. PRP USA, 1 844 377 7787, [email protected]

 

SOURCE Dr. PRP USA


These press releases may also interest you

at 03:00
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
India-Based Dhiti Omics is Now Live on SOPHiA DDMtm
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI: Appointment of Adviser
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
If You Purchased, Paid, or Provided Reimbursement for Some or All of the Price of Branded Lipitor® or its Generic Equivalent, Atorvastatin Calcium, You Could Get Money From a Settlement
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...

3 jui 2024
LOTTE BIOLOGICS Holds Groundbreaking for Songdo Bio Campus
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...

More news about Health...


News published on and distributed by: